Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative cadonilimab plus neoadjuvant chemotherapy in resectable esophageal squamous cell carcinoma
CTR20254678Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Dec 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Akeso, Inc.. Started Dec 2025; status: active.
02
Drugs
cadonilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20254678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254678.